Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) – Zacks Small Cap issued their Q1 2024 earnings per share (EPS) estimates for Tonix Pharmaceuticals in a note issued to investors on Monday, April 29th. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($0.31) for the quarter. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($3.71) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals’ FY2026 earnings at ($0.62) EPS.
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.86) EPS for the quarter. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million.
Get Our Latest Stock Analysis on Tonix Pharmaceuticals
Tonix Pharmaceuticals Trading Up 6.5 %
Shares of TNXP opened at $0.18 on Tuesday. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $3.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. The company’s fifty day simple moving average is $0.27 and its 200-day simple moving average is $0.37.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Sabby Management LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals accounts for 0.5% of Sabby Management LLC’s portfolio, making the stock its 6th largest holding. Sabby Management LLC owned approximately 7.02% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is owned by institutional investors.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Articles
- Five stocks we like better than Tonix Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Trend-Following Entries for Income Investors
- What is Short Interest? How to Use It
- 3 Stocks Mega Investors Are Buying
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Can Disney Stock Triple Before 2030?
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.